Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Nektar commences dosing in NKTR-192 Phase 1 clinical study for treatment of acute pain

Nektar Therapeutics announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate.

2 Apr 2012

Therakos introduces Lighting Up Lives campaign for patients with immune diseases

Therakos, Inc., a pioneer in the development of an innovative immune modulation therapy called extracorporeal photopheresis (ECP), today launched Lighting Up Lives, a 25-year anniversary campaign and year-long global initiative that honours the lives of patients with serious immune diseases impacted by ECP, as well as the healthcare professionals, caregivers and treatment centres that support them every step of the way.

2 Apr 2012

ChemoCentryx fourth quarter revenues increase to $26.1 million

ChemoCentryx, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2011.

31 Mar 2012

Patients with IBD, other GI disorders may be exposed to higher levels of diagnostic radiation

Patients with inflammatory bowel disease (IBD) and other gastrointestinal (GI) disorders may be exposed to significant doses of diagnostic radiation, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.

30 Mar 2012

Althea provides Allena exclusive worldwide rights to broad hyperoxaluria portfolio

Allena Pharmaceuticals, Inc., and Althea Technologies today announced a licensing agreement under which Allena has obtained the exclusive worldwide rights to Althea's broad hyperoxaluria portfolio including product patents, regulatory information and development data related to oxalate degrading enzymes.

29 Mar 2012

Researchers develop gut-on-a-chip microdevice

Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have created a gut-on-a-chip microdevice lined by living human cells that mimics the structure, physiology, and mechanics of the human intestine-even supporting the growth of living microbes within its luminal space.

28 Mar 2012

Pannexins may contribute to symptoms related to IBD

Researchers from the Hotchkiss Brain Institute (HBI) and the Snyder Institute for Chronic Diseases at the University of Calgary's Faculty of Medicine have discovered a pathway that may contribute to the symptoms related to Crohn's disease and ulcerative colitis, collectively known as Inflammatory Bowel Disease.

22 Mar 2012

Study finds higher death rate in calorie-restricted models of IBD

In a surprising result, Michigan State University researchers looking at the effects of diet on bowel disease found that mice on a calorie-restricted diet were more likely to die after being infected with an inflammation-causing bacterial pathogen in the colon.

21 Mar 2012

New information on efficacy of CLA in treating Crohn's disease

The Nutritional Immunology and Molecular Medicine Laboratory (NIMML) research team at Virginia Tech has discovered important new information on the efficacy of conjugated linoleic acid (CLA) in treating Crohn's disease, a form of inflammatory bowel disease (IBD). CLA is a naturally occurring acid found in meat and dairy products known for its anti-cancer and immune modulatory properties.

20 Mar 2012

NIH awards Avaxia $1.5M Phase II SBIR grant to develop antibody therapeutic for IBD

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.

19 Mar 2012

NEJM publishes results from Teva's laquinimod Phase III study on RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced the publication of results from the laquinimod Phase III ALLEGRO study in the March 15 issue of The New England Journal of Medicine.

16 Mar 2012

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

Abbott today announced the initiation of two Phase 3 clinical trials designed to evaluate the safety and efficacy of an investigational use of HUMIRA (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa.

16 Mar 2012

Many children with Crohn's disease and IBD benefit from ImproveCareNow

Many children with Crohn's disease and ulcerative colitis who received treatment through ImproveCareNow, a national quality improvement and research network, ceased to have symptoms and no longer needed to take steroids for disease management.

13 Mar 2012

Five new genetic mutations linked with Crohn's disease in Ashkenazi Jews

In the largest study of its kind, researchers from Mount Sinai School of Medicine have discovered five new genetic mutations associated with Crohn's disease in Jews of Eastern European descent, also known as Ashkenazi Jews.

9 Mar 2012

Even low-dose nanoparticles could have big impact on long-term health

Nanoparticles are everywhere. From cosmetics and clothes, to soda and snacks. But as versatile as they are, nanoparticles also have a downside, say researchers at Binghamton University and Cornell University in a recent paper published in the journal Nature Nanotechnology. These tiny particles, even in low doses, could have a big impact on our long-term health.

9 Mar 2012

BioLineRx granted Israeli approval for BL-7040 Phase II clinical trial for IBD

BioLineRx a biopharmaceutical development company, announced today that it has received approval from the Israeli Ministry of Health for commencing a Phase II clinical trial of BL-7040, an orally available molecule for treating Inflammatory Bowel Disease (IBD).

5 Mar 2012

AARDA hopes to educate public on autoimmune diseases during March

March is National Autoimmune Diseases Awareness Month, and the American Autoimmune Related Diseases Association (AARDA) is working to educate the public on risk factors, prevalence, and the severe lack of awareness surrounding autoimmune diseases.

3 Mar 2012

Mount Sinai receives Le Foundation gift for psychiatric neuroimaging study

The Department of Psychiatry at Mount Sinai School of Medicine has received a $250,000 gift from The Iris & Junming Le Foundation to advance neuroimaging research conducted by young scientists in the early stages of their careers.

23 Feb 2012

Abcodia, Volition announce collaboration agreement

VolitionRX Limited, a life sciences company focused on developing blood-based diagnostic tests, announces a collaboration agreement with Abcodia, a specialist company spun out from University College London (UCL), under which Volition will gain access to Abcodia's biobank of over 5,000,000 human serum samples to validate its suite of NuQ tests.

17 Feb 2012

Preliminary results from Soligenix SGX201 Phase 1/2 trial on acute radiation enteritis

Soligenix, Inc., a development stage biopharmaceutical company, announced preliminary results today from a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.

10 Feb 2012